Form 8-K · Current Report · Filed 2026-08-18
AbbVie Completes Underwritten Public Offering of Senior Notes
On August 18, 2026, AbbVie Inc. completed its previously announced underwritten public offering of various series of senior notes totaling $5.5 billion in aggregate principal amount. The notes, with maturities ranging from 2028 to 2066, were issued under AbbVie's Indenture and are intended to fund a portion of the acquisition of Apogee Therapeutics, Inc., with any remaining proceeds for general corporate purposes. The notes are unsecured and unsubordinated, ranking equally with AbbVie's other unsecured, unsubordinated indebtedness.
- Filer
- AbbVie Inc. ABBV · NYSE
- Filed
- Accession
- 0001104659-26-098367
- CIK
- 0001551152
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$250.40
Since filing
+0.0%
Latest close
$250.40
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from ABBV reporting the same item, with the next session's move:
About AbbVie Inc.
AbbVie Inc. is a prominent biopharmaceutical company that focuses on developing innovative therapies addressing some of the world's most challenging diseases. Originating from a 2013 spinoff of Abbott Laboratories, AbbVie is dedicated to the research and production of pharmaceutical products designed to improve patient outcomes globally. With a robust portfolio, the company specializes in treatments for autoimmune conditions, infectious diseases, oncology, and ophthalmology. Among its flagship products is Humira, widely used for rheumatoid arthritis and inflammatory conditions, which has established AbbVie as a leader in this therapeutic area. The company also invests heavily in research and development, resulting in a pipeline of promising drugs designed to cater to unmet medical needs. AbbVie operates in North America and international markets, serving healthcare providers, researchers, and patients. Its commitment to scientific innovation and high-quality manufacturing standards has positioned it as an influential entity in the healthcare and pharmaceuticals sector.
Never miss another ABBV filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.